Clinical Evaluation of Esthetic Restorations Placed in Primary Molars With Composite Resin Enriched With Insoluble Anti Bacterial Nano Particles (IABN)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00389714 |
Recruitment Status : Unknown
Verified December 2007 by Hadassah Medical Organization.
Recruitment status was: Not yet recruiting
First Posted : October 19, 2006
Last Update Posted : December 11, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Composite resins are presently among the most popular esthetic restorative materials in dentistry. These materials offer excellent esthetic appearance, allow for conservative cavity preparation and are now becoming widely accepted for clinical use in primary molars 1-23. Despite the improvement of their properties, achieved with better materials and incremental placing techniques, composite resin restorations appear to have still several drawbacks: although similar to amalgam in short terms studies, they have a high long term failure rate, mainly due to discoloration, loss of retention and secondary caries3,11,19, are time-consuming and technique sensitive, lack anti-cariogenic potential and can be amenable to secondary caries at the cervical dentin margins 1, 2.
Continued interest in providing advance in restorative esthetic materials led to the development of new generations of composites. Among the newest material developed is the use of minute amount of nanoparticles which convert composites to possess permanent antibacterial properties.
It is of great interest to observe the clinical behavior of this new material when utilized in clinical practice. Thus the aims of the present in-vivo study are:
- To evaluate the clinical and radiographic performance of the New Restorative System when placed with adhesive systems in class II restorations of primary molars.
- To assess, by SEM, the micromorphology of the cervical, buccal and lingual margins of the proximal surfaces of the restored teeth retrieved after exfoliation or extraction.
- To asses, by means of polarized light microscopy, the integrity of the cervical margins of the same retrieved teeth.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Dental Carious Dental Filling | Device: dental restoration | Phase 2 |

Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 60 participants |
Allocation: | Non-Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Double |
Primary Purpose: | Prevention |
Official Title: | Phase 2 Clinical Study :Evaluation of the Efficacy of Insoluble Antibacterial Nanoparticles Incorporated Into Commercialy Used Composit Resins as an Esthetic Restoration Material in Children |
Study Start Date : | February 2007 |

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 5 Years to 10 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- To be eligible to participate in the study the children will have to be between 5 to 10 years old, and present at least two primary molars with a small to moderate proximal carious lesion. These should be in proximal contact with an adjacent tooth and with an antagonist. The children will have to be available for recall appointments every six months until exfoliation of the teeth, and have parental consent to participate in this study.
Exclusion Criteria:
- systemic disorders.
- chemotherapy in the last five years

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00389714
Contact: Michael Perez Davidi, DMD | +972 54 3113780 | michaelpd@hadassah.org.il |
Israel | |
Hadassah Medical Organization | |
Jerusalem, Israel, 46540 | |
Contact: Arik Zukhert, DMD 00 972 2 6776095 arik@hadassah.org.il | |
Contact: Hadas Lemberg, PhD +972543113780 perezdavidi@bezeqint.net | |
Principal Investigator: Michael Perez Davidi, DMD |
Study Director: | Michael Perez Davidi, DMD | Hadassah Medical Organization | |
Study Chair: | Ana Fux, DMD | Hadassah Medical Organization | |
Study Director: | Mordechay Moskovitch, DMD | Hadssah Medical Orgenization |
Publications:
ClinicalTrials.gov Identifier: | NCT00389714 |
Other Study ID Numbers: |
191055nano HMO-CTIL |
First Posted: | October 19, 2006 Key Record Dates |
Last Update Posted: | December 11, 2007 |
Last Verified: | December 2007 |
pedodontics carious dental restoration antibacterial nanoparticles |